Antigenics Inc. - Product Pipeline Review - Q4 2010

Date: November 1, 2010
Pages: 63
Price:
US$ 500.00
License [?]:
Publisher: Global Markets Direct
Report type: Company Report
Delivery: E-mail Delivery (PDF)
ID: AC5FEBCAA2FEN
Leaflet:

Download PDF Leaflet

Antigenics Inc. - Product Pipeline Review - Q4 2010
Antigenics Inc. – Product Pipeline Review – Q4 2010

Summary

Global Market Direct’s pharmaceuticals report, “Antigenics Inc. – Product Pipeline Review – Q4 2010” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope
  • Antigenics Inc. – Brief company overview including business description, key information and facts, and its locations and subsidiaries.
  • Review of current pipeline of Antigenics Inc. human therapeutic division.
  • Overview of pipeline therapeutics across various therapy areas.
  • Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
  • Product profiles for late stage and clinical stage products of Antigenics Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
  • Recent updates of the Antigenics Inc.’s pipeline in the last quarter.
  • Key discontinued and dormant projects.
  • Latest news and deals relating to the products.

Reasons to buy
  • Evaluate Antigenics Inc.’s strategic position with total access to detailed information on its product pipeline.
  • Assess the growth potential of Antigenics Inc. in its therapy areas of focus.
  • Identify new drug targets and therapeutic classes in the Antigenics Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
  • Exploit collaboration and partnership opportunities with Antigenics Inc..
  • Avoid Intellectual Property Rights related issues.
  • Explore the dormant and discontinued projects of Antigenics Inc. and identify potential opportunities in those areas.
Antigenics Inc. Snapshot
Antigenics Inc. Overview
Key Information
Key Facts
Antigenics Inc. – Research and Development Overview
Key Therapeutic Areas
Antigenics Inc. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Antigenics Inc. – Pipeline Products Glance
Antigenics Inc. – Late Stage Pipeline
Phase III Products/Combination Treatment Modalities
Antigenics Inc. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Antigenics Inc. – Drug Profiles
Oncophage
  Product Description
  Mechanism of Action
  R&D Progress
QS-21 Stimulon Adjuvant
  Product Description
  Mechanism of Action
  R&D Progress
Oncophage
  Product Description
  Mechanism of Action
  R&D Progress
AG-707
  Product Description
  Mechanism of Action
  R&D Progress
Antigenics Inc. – Pipeline Analysis
Antigenics Inc. – Pipeline Products by Therapeutic Class
Antigenics Inc. Pipeline Products By Target
Antigenics Inc. – Pipeline Products by Route of Administration
Antigenics Inc. – Pipeline Products by Molecule Type
Antigenics Inc. – Recent Pipeline Updates
Antigenics Inc. - Dormant Projects
Antigenics Inc. - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
Aroplatin
Zintevir
Antigenics Inc. – Company Statement
Antigenics Inc. – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
Oct 25, 2010: Antigenics Expands Phase II Trial In Glioma
Aug 25, 2010: The Fourth Product Candidate Containing Antigenics’ QS-21 In Phase III Clinical Development - GSK Commences Phase III Clinical Trial With Shingles Vaccine Containing QS-21
Aug 25, 2010: The Fourth Product Candidate Containing Antigenics’ QS-21 In Phase III Clinical Development - GSK Commences Phase III Clinical Trial With Shingles Vaccine Containing QS-21
Jul 27, 2010: Antigenics Presents Positive, Top Line Data from Phase I Herpes Clinical Trial
Jul 27, 2010: Antigenics Presents Positive, Top Line Data from Phase I Herpes Clinical Trial
Jul 27, 2010: Antigenics Announces Positive Phase I Trial Results Of AG-707 For Treatment Of Genital Herpes
May 20, 2010: Antigenics Presents Data On Oncophage Vaccine At International Conference On Brain Tumor Research And Therapy
Nov 04, 2009: Antigenics Provides Details On GlaxoSmithKline’s Pivotal Malaria Vaccine Trial With QS-21 Adjuvant
Aug 12, 2009: Antigenics Begins Enrollment Of Patients In Its Phase II Trial Of Oncophage Cancer Vaccine In Newly Diagnosed Glioma
Jun 01, 2009: Antigenics Presents Positive Oncophage Interim Survival Data At ASCO
Financial Deals Landscape
Antigenics Inc., Deals Volume Summary, 2004 to YTD 2010
Antigenics Inc., Deals Summary By Region, 2004 to YTD 2010
Antigenics Inc., Deals Summary, 2004 to YTD 2010
Antigenics Inc. Detailed Deal Summary
Equity Offering
Antigenics Completes Public Offering Of $8.5 Million
Antigenics Completes Private Placement Of $10 Million
Antigenics Completes Private Placement Of $10 Million
Antigenics Completes Private Placement Of $0.8 Million
Antigenics Completes Private Placement Of $21 Million
Antigenics Completes Private Placement Of $26 Million
Antigenics Completes Private Placement Of $5 Million
Antigenics Completes Public Offering Of $57 Million
Debt Offering
Antigenics Completes Private Placement Of 8% Senior Notes For $25 Million
Antigenics Completes Private Placement Of 5.25% Senior Notes For $50 Million
Licensing Agreements
Antigenics Enters Into Licensing Agreement With Johnson & Johnson
GlaxoSmithKline Expands Licensing Agreement With Antigenics
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer 6

LIST OF TABLES

Antigenics Inc. – Pipeline by Therapy Area and Indication, 2010
Antigenics Inc. – Pipeline by Stage of Development, 2010
Antigenics Inc. – Monotherapy Products in Pipeline, 2010
Antigenics Inc. – Phase III, 2010
Antigenics Inc. - Phase II, 2010
Antigenics Inc. - Phase I, 2010
Antigenics Inc. - Pipeline By Therapeutic Class, 2010
Antigenics Inc. - Pipeline By Target, 2010
Antigenics Inc. – Pipeline By Route of Administration, 2010
Antigenics Inc. – Pipeline By Molecule Type, 2010
Antigenics Inc. – Recent Pipeline Updates, 2010
Antigenics Inc. - Dormant Developmental Projects, 2010
Antigenics Inc. - Discontinued Pipeline Products, 2010
Antigenics Inc., Other Locations
Antigenics Inc., Deals Summary, 2004 to YTD 2010
Antigenics Inc., Deals Summary by Region, 2004 to YTD 2010
Antigenics Inc., Deals Summary, 2004 to YTD 2010
Antigenics Completes Public Offering Of $8.5 Million
Antigenics Completes Private Placement Of $10 Million
Antigenics Completes Private Placement Of $10 Million
Antigenics Completes Private Placement Of $0.8 Million
Antigenics Completes Private Placement Of $21 Million
Antigenics Completes Private Placement Of $26 Million
Antigenics Completes Private Placement Of $5 Million
Antigenics Completes Public Offering Of $57 Million
Antigenics Completes Private Placement Of 8% Senior Notes For $25 Million
Antigenics Completes Private Placement Of 5.25% Senior Notes For $50 Million
Antigenics Enters Into Licensing Agreement With Johnson & Johnson
GlaxoSmithKline Expands Licensing Agreement With Antigenics 61

LIST OF FIGURES

Antigenics Inc. – Pipeline by Therapy Area and Indication, 2010
Antigenics Inc. – Pipeline by Stage of Development, 2010
Antigenics Inc. – Monotherapy Products in Pipeline, 2010
Antigenics Inc. – Pipeline By Therapeutic Class, 2010
Antigenics Inc. – Pipeline By Route of Administration, 2010 23

Ask Your Question

Antigenics Inc. - Product Pipeline Review - Q4 2010
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry: